Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.54
+0.32 (2.62%)
Nov 22, 2024, 4:00 PM EST - Market closed
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
85
Market Cap
730.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.59B |
Orthofix Medical | 784.25M |
Bioventus | 555.06M |
Definitive Healthcare | 255.85M |
Butterfly Network | 76.22M |
CGEM News
- 9 days ago - Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewsWire
- 18 days ago - Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - GlobeNewsWire
- 19 days ago - Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - GlobeNewsWire
- 5 weeks ago - Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - GlobeNewsWire